NSCLC AND EMERGING BIOMARKERS: PREDICTIVE ROLE IN PERSONALIZED MEDICINE

• UMBERTO MALAPELLE· PROF. ANAT PATOLOGICA, UNI. DI NAPOLI
• CHRISTIAN ROLFO· DIR. DIV. ONC. MEDICA JAMES CANCER CENTER,OHIO

• NICOLA FUSCO· MODERATORE
• UMBERTO MALAPELLE· RELATORE
• CHRISTIAN ROLFO· RELATORE
• MARCELLO TISEO· MODERATORE

Ragione sociale

MEDICA EDITORIA E DIFFUSIONE SCIENTIFICA S.R.L.

Stato accreditamento

STANDARD - 1° rinnovo

Professionali

The characterization of her2 mutations in patients with non-small cell lung cancer is emerging as a predictive biomarker of response to next-generation targeted therapies. Given the simultaneous assessment of this marker alongside all other essential biomarkers for patients with nsclc (egfr,kras, braf, alk, ros1, ret, met, ntrk and pd-l1), a multidisciplinary discussion is warranted to further explore optimal diagnostic strategies and how to integrate different biological matrices (tissue and liquid biopsy), ensuring that all patients receive appropriate testing.

#1Applicazione nella pratica quotidiana dei principi e delle procedure dell'evidence based practice (EBM - EBN - EBP)

Area: Obiettivi formativi tecnico-professionali

Partecipanti max

100

Verifica presenza

Sistema Elettronico A Badges

Verifica apprendimento

Questionario A Risposta Multipla Online